Amino Acid Conjugates of Aminothiazole and Aminopyridine as Potential Anticancer Agents: Synthesis, Molecular Docking and in vitro Evaluation

Shagufa Naz1,2
Fawad Ali Shah2
Humaira Nadeem1
Sadia Sarwar1
Zhen Tan3
Muhammad Imran1
Tahir Ali4
Jing Bo Li2
Shupeng Li4

1Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, 44000, Pakistan; 2Zhejiang University Clinical Research Center for Neurological Diseases, Health Management Center, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University, Shenzhen, People’s Republic of China; 3Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 4State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, People’s Republic of China

Correspondence: Humaira Nadeem
Riphah Institute of Pharmaceutical Sciences, Riphah International University, G-7/4, 7th Avenue, Islamabad, 44000, Pakistan
Tel +92 51-2891835
Fax +92 51-8350180
Email humaira.nadeem@riphah.edu.pk

Shupeng Li
State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, People’s Republic of China
Email lispl@pku.edu.cn

Purpose: The development of resistance to available anticancer drugs is increasingly becoming a major challenge and new chemical entities could be unveiled to compensate this therapeutic failure. The current study demonstrated the synthesis of 2-aminothiazole [S3 (a-d) and S5(a-d)] and 2-aminopyridine [S4(a-d) and S6(a-d)] derivatives that can target multiple cellular networks implicated in cancer development.

Methods: Biological assays were performed to investigate the antioxidant and anticancer potential of synthesized compounds. Redox imbalance and oxidative stress are hallmarks of cancer, therefore, synthesized compounds were preliminarily screened for their antioxidant activity using DPPH assay, and further five derivatives S3b, S3c, S4c, S5b, and S6c, with significant antioxidant potential, were selected for investigation of in vitro anticancer potential. The cytotoxic activities were evaluated against the parent (A2780) and cisplatin-resistant (A2780CISIR) ovarian cancer cell lines. Further, Molecular docking studies of active compounds were performed to determine binding affinities.

Results: Results revealed that S3c, S5b, and S6c displayed promising inhibition in cisplatin-resistant cell lines in comparison to parent cells in terms of both resistance factor (RF) and IC50 values. Moreover, S3c proved to be most active compound in both parent and resistant cell lines with IC50 values 15.57 μM and 11.52 μM respectively. Our docking studies demonstrated that compounds S3c, S5b, and S6c exhibited significant binding affinity with multiple protein targets of the signaling cascade.

Conclusion: Anticancer activities of compounds S3c, S5b, and S6c in cisplatin-resistant cell lines suggested that these ligands may contribute as lead compounds for the development of new anticancer drugs.

Keywords: thiazole, pyridine, antioxidant activity, anticancer activity, molecular docking

Introduction
Ovarian cancer is considered an immense human health hazard and it is the fifth leading cause of death worldwide. A woman’s risk of getting invasive ovarian cancer is about 1 in 71 during her lifetime.1 Currently, new drug development has focused on the identification of novel targets and/or for ovarian cancer and its inhibitors.2 Over the past decades, most of the chemotherapeutic substances were designed against a specific target in the signaling network. Although these strategies initially increased curative efficacies, but the chances of re-occurrence are prevailing due to the increased resistance rate. Resistance likely develops due to the “rewiring” of subnetworks, including pathway re-programming and cross-activation
in response to external stimuli. Thus, single-target therapies using highly specific compounds would likely fail in cancer treatment unless the compounds can disrupt multiple targets in the network. To deal with this problem, drug strategies called “network medicine” has been recently emerged to combat chemotherapeutic drug resistance. Epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), protein kinase B (PKB/AKT), mitogen-activated protein kinases (MAPKs), anaplastic lymphoma kinase (ALK), cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), phosphoinositide-3-Kinase (PI3K) are the key signaling networks involved in the development of various types of cancers and are inhibited by different anticancer drugs.

Furthermore, cisplatin and other platinum compounds have been used for several types of human malignancies, however, their efficacy is often compromised by tumor resistance. Moreover, currently marketed non-metallic anticancer drugs are also associated with intolerable side effects. To overcome this, new suitable alternative chemical entities must be ruled out which could offer considerable safety and efficacy. Several mechanisms are involved in cisplatin resistance and result in severe limitations in clinical use.

Heterocyclic compounds are of great interest in the field of synthetic organic chemistry and medicinal chemistry. Thiazoles and pyridine are heterocyclic compounds and have demonstrated beneficial biological activities including antidiabetic, antimicrobial, antiviral, anti-inflammatory, anticancer, anti-alzheimer, antihypertensive, antioxidant, and hepatoprotective activities. Anticancer activities of the thiazole scaffold are well established as multiple therapeutically active agents like bleomycin, vosaroxin, echthelines, and dasatinib belong to this class. The groove-binding anticancer agents’ such as dactinomycin, netropsin, and thia-netropsin do also share thiazole moiety in their structure. Other 2-aminothiazole analogues such as giroline and cantharidin exhibited increased apoptotic activity compared to their parent compounds. Moreover, pyridine derivatives such as imatinib mesylate (Gleevec) and aminopyridine derivatives have also been used as potential anticancer agents. Furthermore, free radicals have a significant detrimental propensity for DNA, proteins, and cellular membranes, and thus could exacerbate the pathogenesis of several diseases including cancer. Thus, by decreasing free radical generation and oxidative stress, antioxidants could ameliorate DNA damage, and consequently mutagenesis. Several studies reported the antioxidant activities of 2-aminothiazole and 2-aminopyridine derivatives. There is a great tendency to conjugate amino acid residues with various bioactive heterocyclic compounds in the field of biomedical research. Various products reported by conjugation of amino acid residue with heterocyclic motif resulted in enhanced potency, solubility, cell permeability, selectivity, in vivo stability, and decreased toxicity of heterocycles. Derivatives of aminothiazole with amino acids possess pronounced antibacterial and antifungal activities. Keeping in view the above literature and safety profile of amino acid conjugates, we presented in this study synthesis of new derivatives of ethyl-2-aminothiazole-4-carboxylate and 2-aminopyridine to explore their antioxidant and anticancer potential. Moreover, molecular docking studies against selected proteins from the cell signaling pathway also provided insight into the possible mechanism of active compounds at the molecular level to elaborate the concept of network medicine.

Materials and Methods

Chemistry

General Information

All the starting materials were purchased from Sigma-Aldrich (St. Louis, MO, USA), Daejung (South Korea), and Alfa-Aesar (Germany). Digital Gallenkamp (Sanyo) apparatus was used to record the melting points of final compounds and was uncorrected. Proton NMR (1H NMR) and carbon-13 (13C NMR) spectra were measured on a Bruker AV 400 spectrophotometer in CD3OD, CDC13, and DMSO-d6 at 400 MHz using TMS (Tetramethylsilane) as an internal standard. Alpha Bruker FTIR spectrophotometer (ATR eco ZnSe, vmax in cm⁻¹) was used to record FTIR spectra and elemental analysis was conducted using a LECO-183 CHNS analyzer. All reactions were monitored by thin-layer chromatography (TLC). Merck silica gel HF-254 was used for column chromatographic purification of products using (pet.ether: ethyl acetate, 4:1) as eluent. All chemicals used were of high analytical grade (99% HPLC).

General Procedure for the Preparation of Ethyl-2-Aminothiazole-4-Carboxylate (3)

A mixture of ethyl bromopyruvate (0.05 mol, 9.75 g) and thiourea (0.10 mol, 7.61 g) in absolute ethanol (53 mL) was refluxed for 24 h. The completion of the reaction was
checked by thin layer chromatography (TLC). After completion, the reaction mixture was allowed to cool to room temperature and concentrated in vacuo to half the original volume. The remaining ethanol solution was poured into water and made alkaline (pH 10) with 2N NaOH. Light brown solid precipitated immediately. The mixture was stirred for about 10 min and then the solid was removed by vacuum filtration and dried to give the desired product.47

**Ethyl 2-Amino-1,3-Thiazole-4-Carboxylate (3)**

Light brown crystals; yield: 68%; m.p. found: 176 °C; m.p. reported: 175–180 °C; Rf = 0.18 (pet. ether:ethyl acetate 3:1); FTIR (vmax cm−1) 3290 (NH2, str.), 1733 (C=O, ester, str.), 1615 (C=N, str.), 1540 (C=C, str.); 1H NMR (400 MHz, CD3OD) δ ppm 7.4 (s, 1H, H-1), 5.8 (brs, 2H, NH2), 4.32 (q, J=7.2Hz, 2H, H-2), 1.35 (t, J=7.2Hz, 3H, H-3); 13C NMR (400 MHz, CD3OD) δ ppm 167.8, 161.5, 148.2, 116.7, 61.3, 15.2; Anal. calcd for C6H10O2N2S (172.20): C, 41.86; N, 16.27; H, 4.68. Found: C, 41.79; N, 16.19; H, 4.61%.

**General Procedure for the Preparation of N, N-Phthaloyl Protected Amino Acids (S1a-S1d)**

A mixture of respective amino acids (0.03 mol) and finely ground phthalic anhydride (0.03 mol, 4.44 g) was heated with stirring in an oil bath at 185–190°C for 30 min. After cooling, the solid material was dissolved in hot methanol (20 mL) and filtered. The product was allowed to crystallize out slowly in appropriate solvent (methanol/water, 1:1).48

**(1,3-Dioxo-1,3-Dihydro-2H-Isoindol-2-yl)acetic Acid (S1a)**

White crystals; yield: 90%; m.p. found: 197 °C; m.p. reported: 197–198 °C; Rf = 0.64 (ethyl acetate:pet.ether 3:1); FTIR (vmax cm−1) 1716 (C=O, acid, str.), 1632, 1536 (C=O, phthaloyl amide, str.); 1H NMR (400 MHz, CD3OD) δ ppm 7.91–7.79 (m, 4H, Ar-H), 4.52 (s, 2H, H-4); 13C NMR (400 MHz, CD3OD) δ ppm 170, 167.8, 167.2, 134.7, 133.9, 131.9, 131.3, 122.6, 122.1, 38.7; Anal. calcd for C16H10O2N (205.16): C, 58.53; N, 6.82; H, 3.41. Found: C, 58.51; N, 6.79; H, 3.38%.

**(2-(1,3-Dioxo-1,3-Dihydro-2H-Isoindol-2-yl)-3-Phenylpropanoic Acid (S1b)**

White crystals; yield: 91%; m.p. found: 177 °C; m.p. reported: 178 °C; Rf = 0.71 (ethyl acetate:pet.ether 3:1); IR (vmax cm−1) 1714 (C=O, acid, str.), 1636,1534 (C=O, phthaloyl amide, str.); 1H NMR (400 MHz, CD3OD) δ ppm 7.90–7.77 (m, 8H, Ar-H), 5.41 (d, J=4.8Hz, 1H, H-4), 3.67 (m, 2H, H-5); 13C NMR (400 MHz, CD3OD) δ ppm 176.5, 168.6, 168.1, 138.4, 135.8, 134.7, 131.6, 131.2, 128.2, 127.7, 125.5, 121.8, 117.5, 117.2, 62.5, 35.3; Anal. calcd for C17H13O,N (295.28): C, 69.15; N, 47.45; H, 4.41. Found: C, 69.05; N, 47.40; H, 4.38%.

**(2-(1,3-Dioxo-1,3-Dihydro-2H-Isoindol-2-yl)-4-Methylpentanoic Acid (S1c)**

White crystals; yield: 83%; m.p. found: 110 °C; m.p. reported: 110 °C; Rf = 0.73 (ethyl acetate:pet.ether 3:1); FTIR (vmax cm−1) 1718 (C=O, acid, str.), 1633,1532 (C=O, phthaloyl amide, str.); 1H NMR (400 MHz, CD3OD) δ ppm 7.91 (d, 2H, J=8Hz, H-8,8′, Ar-H), 7.78 (d, J=8Hz, 2H, H-9,9′, Ar-H), 5.06 (dd, J1,J2=4.8Hz, 1H, H-4), 2.40 (m, 2H, H-5), 1.54 (m, 1H, H-6), 1.0 (d, J=6.4Hz, 6H, H-7a,7b); 13C NMR (400 MHz, CD3OD) δ ppm 180.3, 169.9, 169.3, 137.4, 136.3, 128.7, 128.4, 120.5, 120.1, 63.2, 37.5, 26.8, 20.9, 19.3; Anal. calcd for C14H13O4N (261.27): C, 64.36; N, 5.36; H, 5.75. Found: C, 64.30; N, 5.33; H, 5.71%.

**(2-(1,3-Dioxo-1,3-Dihydro-2H-Isoindol-2-yl)-3-Methylpentanoic Acid (S1d)**

White crystals; yield: 75%; m.p. found: 112 °C; m.p. reported: 110–112 °C; Rf = 0.8 (ethyl acetate:pet.ether 3:1); FTIR (vmax cm−1) 1716 (C=O, acid, str.), 1637,1530 (C=O, phthaloyl amide, str.); 1H NMR (400 MHz, CD3OD) δ ppm 7.87–7.79 (m, 4H, Ar-H), 4.60 (d, J=8Hz, 1H, H-4), 2.87 (m, 1H, H-5), 1.57 (m, 2H, H-6), 1.11 (d, J=8Hz, 3H, H-10), 0.91 (t, J=8Hz, 3H, H-7); 13C NMR (400 MHz, CD3OD) δ ppm 174.6, 165.7, 165.3, 135.5, 134.4, 127.8. 126.3, 118.7, 118.4, 65.3, 36.8, 23.2, 16.6, 10.5; Anal. calcd for C14H15O4N (261.27): C, 64.36; N, 5.36; H, 5.75. Found: C, 64.29; N, 5.30; H, 5.67%.

**General Procedure for the Preparation of N, N-Phthaloyl Amino Acid Chlorides (S2a-S2d)**

To a solution of respective N,N-phenylalanyl amino acids (0.005 mol) in dichloromethane (25 mL), thionyl chloride (0.015 mol, 1.08 mL) was added and refluxed for 8 h. The progress of the reaction was monitored by TLC and after the completion, the excess of thionyl chloride was evaporated. The resulting product was used without further purification.49

**General Procedure for the Preparation of Amides (S3a-S3d and S4a-S4d)**

To a solution of respective N,N-phenylalanyl amino acid chlorides (0.01 mol) in 20 mL of dichloromethane and 5 mL DMF
(dimethylformamide), (0.01 mol, 2.06 g) of DCC (dicyclohexyl carbodiimide) was added. The reaction mixture was stirred for 0.5 h followed by the dropwise addition of ethyl 2-aminothiazole-4-carboxylate (0.01 mol, 1.72 g) or 2-aminopyridine (0.01 mol, 0.94 g) previously dissolved in 20 mL of dichloromethane. Further, the reaction mixture was stirred at 45°C for 2 h followed by overnight stirring at room temperature. The completion of the reaction was checked by TLC (pet.ether: ethyl acetate, 3:1). After completion, the mixture was allowed to cool, resulted in white dicyclohexylurea precipitates which were further removed by filtration. The excess of solvent was removed under reduced pressure and the corresponding product was dried and recrystallized from chloroform.50

Ethyl-2-[(1,3-Dioxo-1,3-Dihydro-2H-Isoindol-2-yl)acetyl]amino]-1,3-Thiazole-4-Carboxylate (S3a)
Brown solid; yield: 72%; m.p. 171 °C; Rf = 0.37 (pet.ether: ethyl acetate 3:1); FTIR (vmax cm⁻¹) 3298 (N-H, str.), 1726 (C=O, ester, str.), 1698 (C=O, amide, str.), 1631,1539 (C=O, phthaloyl amide, str.); ¹H NMR (400 MHz, CDCl₃) δ ppm 9.25 (brs,1H, NH), 7.90–7.78 (m, 4H, aromatic), 7.28 (s, 1H, H-1), 4.52 (s, 2H, H-4), 3.74 (q, J=7.2Hz, 2H, H-2), 1.3 (t, J=7.2Hz, 3H, H-3); ¹³C NMR (400 MHz, CDCl₃) δ ppm 190.1, 170.4, 167.5, 167.1, 158.2, 139.4, 133.6, 131.3, 130.4, 129.5, 123.8, 123.1, 113.5, 48.4, 39.6, 69; Anal. calcd for C₁₄H₁₀O₃N₂S (343.35): C, 53.48; N, 11.69; H, 3.62. Found: C, 52.70; N, 10.45; H, 3.10%.

Ethyl-2-[(2-(1,3-Dioxo-1,3-Dihydro-2H-Isoindol-2-yl)-3-Phenyl)amino]-1,3-Thiazole-4-Carboxylate (S3b)
White crystals; yield: 88%; m.p. 153 °C; Rf = 0.29 (pet.ether: ethyl acetate 3:1); FTIR (vmax cm⁻¹) 3322 (N-H, str.), 1730 (C=O, ester, str.), 1695 (C=O, amide, str.), 1626,1546 (C=O, phthaloyl amide, str.); ¹H NMR (400 MHz, CDCl₃) δ ppm 10.11 (brs,1H, NH), 7.85–7.77 (m, 8H, Ar-H), 7.17 (s, 1H, H-1), 5.39 (d, J=4.8Hz, 1H, H-4), 4.42 (q, J=7.2Hz, 2H, H-2), 3.67 (m, 2H, H-5), 1.40 (t, J=7.2Hz, 3H, H-3); ¹³C NMR (400 MHz, CDCl₃) δ ppm 191.2, 170.5, 167.7, 167.3, 156.4, 138.2, 137.4, 133.8, 132.1, 131.4, 131.0, 129.8, 129.1, 128.7, 128.2, 123.5, 123.3, 115.4, 58.2, 37.9, 35.2, 8.3; Anal. calcd for C₁₉H₁₄O₃N₂S (433.47): C, 61.46; N, 9.35; H, 4.23. Found: C, 60.39; N, 8.51; H, 3.95%.

Ethyl-2-[(2-(1,3-Dioxo-1,3-Dihydro-2H-Isoindol-2-yl)-4-Methylpentanoylamino)-1,3-Thiazole-4-Carboxylate (S3c)
White crystals; yield: 86%; m.p. 79 °C; Rf = 0.36 (pet.ether: ethyl acetate 3:1); FTIR (vmax cm⁻¹) 3359 (N-H, str.), 1733 (C=O, ester, str.), 1696 (C=O, amide, str.), 1650,1563 (C=O, phthaloyl amide, str.); ¹H NMR (400 MHz, CDCl₃) δ ppm 9.78 (brs,1H, NH), 7.91–7.83 (m, 4H, Ar-H), 7.29 (s, 1H, H-1), 5.19 (dd, J₁,J₂=4.8Hz, 1H, H-4), 4.42 (q, J=7.2Hz, 2H, H-2), 2.20 (m, 1H, H-6), 1.60 (m, 2H, H-5), 1.41 (t, J=7.2Hz, 3H, H-3), 1.0 (d, J=6.4Hz, 6H, H-7a,7b); ¹³C NMR (400 MHz, CDCl₃) δ ppm 189.4, 171.2, 168.5, 167.8, 157.1, 138.4, 134.4, 133.1, 132.4, 124.6, 123.1, 117.5, 61.8, 36.9, 33.5, 26.2, 23.4, 22.5, 7.4; Anal. calcd for C₂₀H₂₃O₃N₂S (399.46): C, 57.83; N, 10.12; H, 5.06. Found: C, 56.45; N, 9.89; H, 4.82%.

Ethyl-2-[(2-(1,3-Dioxo-1,3-Dihydro-2H-Isoindol-2-yl)-3-Methylpentanoylamino)-1,3-Thiazole-4-Carboxylate (S3d)
White crystals; yield: 78%; m.p. 174 °C; Rf = 0.34 (pet.ether: ethyl acetate 3:1); FTIR (vmax cm⁻¹) 3320 (N-H, str.), 1728 (C=O, ester, str.), 1692 (C=O, amide, str.), 1642,1521 (C=O, phthaloyl amide, str.); ¹H NMR (400 MHz, CDCl₃) δ ppm 10.32 (brs,1H, NH), 7.87–7.79 (m, 4H, Ar-H), 7.28 (s, 1H, H-1), 4.78 (q, J=7.2Hz, 2H, H-2), 4.43 (d, J=8Hz, 1H, H-4), 2.87 (m, 1H, H-5), 1.57 (m, 2H, H-6), 1.42 (t, J=7.2Hz, 3H, H-3), 1.11 (d, J=8Hz 3H, H-10), 0.91 (t, J=8Hz, 3H, H-7); ¹³C NMR (400 MHz, CDCl₃) δ ppm 190.4, 171.5, 167.5, 167.1, 156.3, 139.4, 133.6, 133.1, 132.8, 131.7, 123.6, 123.1, 115.3, 58.5, 34.2, 31.5, 27.2, 19.2, 12.6, 6.8; Anal. calcd for C₂₀H₂₃O₃N₂S (399.46): C, 57.83; N, 10.12; H, 5.06. Found: C, 56.58; N, 9.91; H, 4.87%.
amide, str.); 1H NMR (400 MHz, CDCl3) δ ppm 9.85 (brs, 1H, NH), 8.63 (d, J=4.3 Hz, 1H, pyridine), 8.30 (d, J=8Hz, 1H, pyridine), 7.81 (t, J=7.7Hz, 1H, pyridine), 7.70 (dd, J1,J2=7.1Hz, 1H, pyridine), 7.20–7.06 (m, 9H, Ar-H), 5.31 (d, J=4.8 Hz, 1H, CH-α-carbon), 3.69 (m, 2H, CH2-phenyl); 13C NMR (400 MHz, CDCl3) δ ppm 171.2, 167.1, 166.9, 152.3, 148.2, 139.6, 137.2, 134.2, 133.5, 131.5, 129.9, 129.1, 127.5, 126.9, 125.8, 124.8, 123.7, 118.2, 113.7, 62.6, 39.2; Anal. calcd for C23H19O3N2S (433.47): C, 61.46; N, 9.35; H, 4.23. Found: C, 61.39; N, 9.31; H, 4.20%.

2-(1,3-Dioxo-1,3-Dihydro-2H-Isindol-2-yl)-4-Methyl-N-(Pyridin-2-yl)pentanamide (S4e)
White crystals; yield: 60%; m.p. 109 °C; Rf = 0.325 (pet. ether:ethyl acetate 3:1); FTIR (v_max cm⁻¹) 3343 (N-H, str.), 1697 (C=O, amide, str.), 1635,1542 (C=O, phthaloyl amide, str.); 1H NMR (400 MHz, CDCl3) δ ppm 9.68 (brs, 1H, NH), 8.65 (d, J=4Hz, 1H, pyridine), 8.29 (d, J=7.9Hz, 1H, pyridine), 7.92 (t, J=7.8Hz, 1H, pyridine), 7.79 (dd, J1,J2=7Hz, 1H, pyridine), 7.28–7.06 (m, 4H, Ar-H), 5.11 (t, J=5Hz, 1H, CH-α-carbon), 2.01 (m, 1H, -CH(CH3)-2-leucine), 1.56 (dd, 2H, -CH2-2-leucine), 1.0 (d, 6H, J=6.4Hz, -CH2(CH3)-2-leucine); 13C NMR (400 MHz, CDCl3) δ ppm 171.6, 167.9, 167.1, 157.4, 148.4, 136.5, 134.8, 134.2, 132.9, 131.4, 125.8, 124.2, 118.4, 115.5, 69.5, 38.7, 30.4, 29.5, 23.5; Anal. calcd for C20H22O2N4S (399.44): C, 57.83; N, 10.12; H, 5.06. Found: C, 57.80; N, 10.02; H, 5.02%.

General Procedure for N-Deprotection of Amino Acids (SSa-SSd and S6a-S6d)
To a solution of respective phthalimides (0.01 mol) in boiling ethanol (22 mL), hydrazine hydrate 50% (0.01 mol, 0.32 g) was added. The completion of the reaction was checked by TLC. On cooling, the precipitates were collected, and recrystallized from ethanol.51

2-Amino-N-[4-(Hydrazinylcarbonyl)-1,3-Thiazol-2-yl]acetamide (SSa)
Brown solid; yield: 62%; m.p. 195 °C; Rf = 0.37 (pet. ether:ethyl acetate 3:1); FTIR (v_max cm⁻¹) 3298 (N-H, str.), 3276 (N-H, str.), 3268 (NH2, str.), 3263 (NH2, str.), 1698 (C=O, amide, str.), 1646 (C=O, amide, str.); 1H NMR (400 MHz, DMSO-d6) δ ppm 9.25 (brs, 1H, NH), 8.79 (s, 1H, NHCO), 7.28 (s, 1H, H-1), 4.52 (s, 2H, H-4), 4.38 (s, 2H, NH2NH), 4.25 (s, 2H, NH2); 13C NMR (400 MHz, DMSO-d6) δ ppm 169.8, 162.4, 159.4, 150.4, 114.5, 45.2; Anal. calcd for C8H10O2N6S (215.23): C, 33.48; N, 32.54; H, 4.21. Found: C, 33.42; N, 32.40; H, 4.10%.

2-Amino-N-[4-(Hydrazinylcarbonyl)-1,3-Thiazol-2-yl]-3-Phenylpropanamide (SSb)
Light brown solid; yield: 88%; m.p. 206 °C; Rf = 0.29 (pet.ether:ethyl acetate 3:1); FTIR (v_max cm⁻¹) 3299 (N-H, str.), 3273 (N-H, str.), 3269 (NH2, str.), 3261 (NH2, str.), 1696 (C=O, amide, str.), 1646 (C=O, amide, str.); 1H NMR (400 MHz, DMSO-d6) δ ppm 10.11 (brs, 1H, NH), 8.89 (s, 1H, NHCO), 7.85–7.77 (m, 5H, Ar-H), 7.17 (s, 1H, H-1), 5.39 (d, J=4.8Hz, 1H, H-4), 4.39 (s, 2H, NH2NH), 4.28 (s, 2H, NH2), 3.67 (m, 2H, H-5); 13C NMR (400 MHz, DMSO-d6) δ ppm 174.2, 163.7, 160.1, 150.2, 137.4, 129.8, 128.5, 128.1, 127.9, 126.3, 120.5, 49.8, 34.2; Anal. calcd for C19H14O2N6S (305.35): C, 51.13; N, 22.94; H, 4.95. Found: C, 51.10; N, 22.89; H, 4.92%.

2-Amino-N-[4-(Hydrazinylcarbonyl)-1,3-Thiazol-2-yl]-4-Methylpentanamide (SSc)
Orange solid; yield: 70%; m.p. 198 °C; Rf = 0.36 (pet. ether:ethyl acetate 3:1); FTIR (v_max cm⁻¹) 3298 (N-H, str.), 3275 (N-H, str.), 3266 (NH2, str.), 3260 (NH2, str.), 1695 (C=O, amide, str.), 1647 (C=O, amide, str.); 1H NMR (400 MHz, DMSO-d6) δ ppm 9.78 (brs, 1H, NH), 8.77 (s, 1H, NHCO), 7.29 (s, 1H, H-1), 5.19 (dd, J1,J2=4.8Hz, 1H, H-4), 4.38 (s, 2H, NH2NH), 4.26 (s, 2H, NH2), 2.20 (m, 1H, H-6), 1.60 (m, 2H, H-5), 1.0 (d, J=6.4Hz, 6H, H-7a,7b); 13C NMR (400 MHz, DMSO-d6) δ ppm 170.4, 161.5, 158.2, 147.8, 114.5, 53.1, 45.1, 20.4, 19.2, 17.3;
2-Amino-N-[4-(Hydrazinylcarbonyl)-1,3-Thiazol-2-yl]-3-Methylpentanamide (S5d)
Brown solid; yield: 78%; m.p. 161 °C; Rf = 0.34 (pet.ether: ethyl acetate 3:1); FTIR (νmax cm⁻¹) 3301 (N-H, str.), 3278 (N-H, str.), 3265 (NH₂, str.), 3262 (NH₂, str.), 1692 (C=O, amide, str.), 1646 (C=O, amide, str.); 1H NMR (400 MHz, DMSO-d₆) δ ppm 10.32 (bs, 1H, NH), 8.79 (s, 1H, NHCO), 7.28 (s, 1H, H-1), 4.43 (d, J=8Hz, 1H, H-4), 4.37 (s, 2H, NH₂NH), 4.28 (s, 2H, NH₂), 2.87 (m, 1H, H-5), 1.57 (m, 2H, H-6), 1.11 (d, J=8Hz 3H, H-10), 0.91 (t, J=8Hz, 3H, H-7); 13C NMR (400 MHz, DMSO-d₆) δ ppm 172.4, 164.4, 158.9, 146.1, 116.5, 58.5, 39.4, 24.8, 18.4, 10.1; Anal. calcld for C₁₀H₁₂O₂N₃S (271.33): C, 44.26; N, 25.81; H, 6.31. Found: C, 44.21; N, 25.79; H, 6.28%.

2-Amino-N-(Pyridin-2-yl)acetamide (S6d)
White crystals; yield: 75%; m.p. 236 °C; Rf = 0.35 (pet.ether: ethyl acetate 3:1); FTIR (νmax cm⁻¹) 3310 (N-H, str.), 3270 (NH₂, str.), 1695 (C=O, amide, str.); 1H NMR (400 MHz, DMSO-d₆) δ ppm 9.96 (bs, 1H, NH), 9.49 (d, J=4Hz, 1H, H-3'), 8.32 (d, J=8Hz, 1H, H-6'), 8.20 (t, J=7.8Hz, 1H, H-4'), 7.90 (dd, J₁,J₂=7.2Hz, 1H, H-5'), 4.66 (d, J=8Hz, 1H, H-4), 4.29 (s, 2H, NH₂), 2.87 (m, 1H, H-5), 1.57 (m, 2H, H-6), 1.11 (d, J=8Hz, 3H, H-10), 0.91 (t, J=8Hz, 3H, H-7); 13C NMR (400 MHz, DMSO-d₆) δ ppm 170.4, 152.4, 149.8, 138.6, 118.5, 114.3, 58.5, 35.7, 26.4, 18.3, 12.2; Anal. calcld for C₁₁H₁₇ON₃ (207.27): C, 63.74; N, 20.27; H, 8.27. Found: C, 63.70; N, 20.25; H, 8.23%.

In vitro Antioxidant Activity
To preliminarily evaluate the free radical scavenging potential of synthesized derivatives; an in vitro antioxidant activity assay was performed using DPPH.²² For the relative assay, a solution containing DPPH (3 mL) and methanol (1 mL) was designated as a negative control. Ascorbic acid was used as a reference standard. Different concentrations of test compounds were taken up to 3 mL and, 1 mM DPPH solution in methanol was added. These mixtures were kept for 30 min under dark. UV spectrophotometer was used to assess the free radical scavenging potential of test compounds through measuring absorbance at 517 nm. The inverse relationship between absorbance and test compound concentrations shows antioxidant potential. Furthermore, the color change also presents a potential indication that is from blue color to yellowish-orange color. Percent scavenging efficacy was determined using the formula:

\[ \text{% radical scavenging} = \left( \frac{\text{absorbance of control} - \text{absorbance of test sample}}{\text{absorbance of control}} \right) \times 100 \]

In vitro Anticancer Activity
Preparation of Cells
Human ovarian cancer cell lines A2780 and A2780CIS were purchased from ECACC (93112519, 93112517 for
A2780 and A2780CISR respectively). The ovarian cancer cell lines A2780 (parent) and A2780CISR (cisplatin-resistant) were grown in tissue culture flasks in an incubator at 37 °C in a humidified atmosphere of 5% CO₂ and 95% air. 4500 to 5500 cells per well in 10% FCS/RPMI 1640 culture medium were seeded into flat-bottomed 96-well culture plates and allowed to attach overnight. Cells were counted by Bio-Rad TC10 automated cell counter. 10µL of cell suspension was loaded onto the slide and inserted into the counter to count automatically. After counting cells, cell lines were seeded in two separate 96 well plates. 100 µL of cell mixture (cells in the medium) were added to each well. Prepared drug concentrations are shown in Table 1. The plates were incubated for 24 h at 37 °C in a humidified atmosphere to allow the cells to attach.

| Drugs      | Final Concentration of Drugs After Addition to Cells (µM) |
|------------|----------------------------------------------------------|
| Cisplatin  | 0.16–20                                                  |
| S5b        | 0.16–20                                                  |
| S6c        | 0.16–20                                                  |
| S3b        | 1.6–200                                                  |
| S3c        | 1.6–200                                                  |
| S4c        | 1.6–200                                                  |

**Figure 1** Synthesis of 2-aminothiazole and 2-aminopyridine derivatives.
Drug Addition to Cells

After the preparation of fivefold serial dilutions of the drugs in 10% FCS/RPMI 1640 medium, 100 μL of each drug were added to equal volumes of cell culture in triplicate wells. The plates were then left to incubate in the carbon dioxide incubator (5% carbon dioxide in the air, pH 7.4) for 72 h at 37 °C in a humidified atmosphere.

MTT Reduction Assay

MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazo- lium bromide] powder was dissolved in serum-free- RPMI-1640 medium at 1 mg/mL and filtered using DISMIC-25cs ADVANTEC cellulose acetate filter to remove any unwanted particles. The medium was removed and 50 μL of the MTT solution was added to each well of 96-well plate and incubated for 4 h in the same carbon dioxide incubator. Cisplatin was used as a standard drug. After incubation, the MTT solution was removed and 150 μL of DMSO was added to each well. The living cells if still present remained attached at the bottom. The yellow formazan crystals produced from the reduction of MTT was dissolved in DMSO and the optical density (OD) of the resulting solution was read with the Bio-Rad, Microplate Reader, Benchmark at 570 nm. The survival cell fractions were calculated according to the following equation of Mosmann (1983).

Figure 2 Proposed reaction mechanism to synthesize compound S5.
Survival cell fractions = \(
\frac{\text{OD of Treated cells} - \text{OD of DMSO}}{\text{OD of control} - \text{OD of DMSO}}
\)

Dosage response curves have been constructed by plotting the percentage of viable cells against drug concentration. The drug concentration required to cause 50% cell death (IC\(_{50}\) value) was then calculated from the curve. For each drug concentration, at least three independent experiments were performed.\(^5\) RF (Resistance factor) was also calculated using the following formula.\(^4\)

\[
\text{Resistance factor} = \frac{\text{IC}_{50} \text{ in resistance cell line}}{\text{IC}_{50} \text{ in parent cell line}}
\]

**Molecular Docking**

Molecular docking studies of the compounds S3c, S5b and S6c with better in vitro anticancer activities were performed against eleven protein targets, selected from cell signaling pathways (ie, EGFR, VEGFR, PDGFR, p110\(^{\text{p}}\)PI3K, RET, BCR-ABL, c-KIT, c-Raf, B-Raf, CTLA-4 and ALK) (PDB Codes: 1E90, 4LL0, 4AG8, 2L6W, 1ZZP, 2IVU, 3G0E, 3OMV, 2YJR, 3PPJ, 3OSK, respectively).

Structures of selected ligands ie S3c, S5b and S6c and standard inhibitors were prepared in ChemSketch and saved as mol files. Open Bable software was used to convert 2 dimensional (2D) structures to 3D.\(^5\) Accelrys Discovery Studio Visualizer (version 4.1) was used to convert the structures in PDB file format for use in AutoDock Vina.\(^5\) The 3-dimensional crystal structures of cancer targets (proteins and DNA) were retrieved from the RCSB Protein Data Bank (\texttt{http://www.rcsb.org/pdb}). The proteins were set up for docking by removing attached ligand and crystallographic water molecules using Accelrys Discovery Studio Visualizer (version 4.1). The optimized proteins were then saved as a PDB file format for docking.

Molecular docking studies were performed using AutoDock Vina software (version 1.5.6)\(^6\) to determine binding affinities of ligands with respective protein targets and their binding energy values were also compared with anticancer standard drugs against respective targets. The AutoDock tool was used to add polar hydrogens in a protein molecule. The binding site for docking was designed such that the entire receptor molecule was included within the selection grid. Default parameters were used for docking. Binding affinities of synthesized and standard ligands were analyzed based on minimum binding energy values. Ligand protein binding interactions of complexes with minimum docking scores were analyzed using Accelrys Discovery Studio Visualizer (version 4.1).

**Statistical Analysis**

Graph Pad Prism 6.0 (Graph-Pad, San Diego, CA, United States) was used to analyze the data. For biochemical data, one way-ANOVA followed by Tukey’s post hoc test was applied. Data were demonstrated as mean ± SEM. Significant statistical differences were at *\(p < 0.05\).

**Results**

**Chemistry**

New derivatives of Aminothiazole and aminopyridine derivatives were synthesized using the scheme given in Figure 1. Initially, the nitrogen group of amino acids was protected using phthalic anhydride S1(a-d). These were further reacted with thionyl chloride to yield corresponding acid chlorides and condensed with ethyl-2-aminothiazole-4-carboxylate and 2-aminopyridine to afford corresponding amide derivatives S3(a-d) and S6.

![Figure 3 Proposed reaction mechanism to synthesize compound S6.](image-url)
**Figure 4** DPPH radical scavenging activity of synthesized derivatives.

S4(a-d) respectively. Finally, the N-deprotection of compounds S3(a-d) and S4(a-d) was carried out in the presence of hydrazine hydrate to yield compounds S5(a-d) and S6(a-d). The respective reaction mechanisms for N-deprotection of compounds S3 and S4 are shown in Figures 2 and 3 respectively.

In the FTIR spectra, the presence of amide stretch in compounds S3(a-d) and S4(a-d) ranging 1698–1690 cm⁻¹ confirmed the formation of an amide linkage. Further, the ¹H-NMR data of synthesized analogues presented a singlet of -NH proton ranging δ = 10.32–9.11 ppm, indicated the formation of coupled products. Similarly, in the case of S5(a-d) and S6(a-d) derivatives, the disappearance of carbonyl stretch for phthaloyl moiety in the range of 1635–1552 cm⁻¹ confirmed the de-protection of amino acids.

In vitro Antioxidant Activity

2,2-diphenyl-1-picrylhydrazyl (DPPH) method was used to evaluate the antioxidant potential of newly synthesized compounds [S3(a-d), S4(a-d), S5(a-d), S6(a-d)] and the results are summarized in Figure 4. The antioxidant potential was calculated as the change in absorbance relative to the reference control. Probit regression was used to calculate EC₅₀ values due to the non-linearity in regression.³³ Compounds S3b, S3c, S4c, S5b, and S6c showed significant activities with EC₅₀ values, 16.25 µg/mL, 14.16 µg/mL, 17.03 µg/mL, 12.97 µg/mL, and 15.19 µg/mL respectively to the reference ascorbic acid which was found as 10.41 µg/mL. Based on this preliminary assay, we selected five compounds (S3b, S3c, S4c, S5b, and S6c) for evaluation of their in vitro anticancer potential.

In vitro Anticancer Activity

Synthesized derivatives S3b, S3c, S4c, S5b, and S6c exhibited relative significant antioxidant activities were further evaluated for anticancer potential in parent and cisplatin-resistant ovarian cancer cell lines, A2780 and A2780CISR respectively, while cisplatin was used as a standard drug. IC₅₀ and the resistance factor (RF) values of standard drug cisplatin and tested compounds are given in Table 2. All the tested compounds exhibited

**Table 2** Anticancer Activity of the Synthesized Thiazole and Pyridine Derivatives Against A2780 (Parent) and A2780CISR (Cisplatin-Resistant) Ovarian Cancer Cell Lines, Expressed as IC₅₀ Values and Compared to Cisplatin, the Standard Drug

| Tested Compounds | IC₅₀ (µM) |
|------------------|----------|
|                  | A2780*   | A2780CISR** | RF* |
| S3b              | 38.56 ± 1.98 | 54.76 ± 2.80 | 1.42 |
| S3c              | 15.57 ± 2.37 | 11.52 ± 2.81 | 0.74 |
| S4c              | 39.14 ± 1.79 | 51.21 ± 1.65 | 1.31 |
| S5b              | 25.57 ± 2.83 | 14.32 ± 1.22 | 0.56 |
| S6c              | 31.45 ± 0.02 | 15.41 ± 1.52 | 0.49 |
| Cisplatin        | 0.61 ± 0.06 | 16.43 ± 1.45 | 26.93 |

**Notes:** *Parent ovarian cancer cell line. **Cisplatin resistant ovarian cancer cell line. *Resistance factor.
a dose-dependent anti-proliferative effect against parent and cisplatin-resistant ovarian cancer cell lines. We demonstrated that compounds S3c, S5b, and S6c reversed the cisplatin resistance of cancer cells with IC\textsubscript{50} values 11.52 \(\mu\)M, 14.32 \(\mu\)M, and 15.41 \(\mu\)M respectively relative to the standard drug cisplatin with IC\textsubscript{50} values 16.43 \(\mu\)M. Furthermore, RF values for all the tested compounds S3b, S3c, S4c, S5b, and S6c were respectively 1.42, 0.74, 1.31, 0.56, and 0.49, while for cisplatin was 26.93. Moreover, compounds S3c, S5b, and S6c exhibited more potency in cisplatin-resistant cell lines than the parent cells by displaying less IC\textsubscript{50} values, associated with RF values of 0.74, 0.56, and 0.49 respectively. Furthermore, derivative S3c demonstrated inhibitory effects both in parent and cisplatin-resistant ovarian cancer cell lines with an IC\textsubscript{50} value of 15.57 \(\mu\)M, 11.52 \(\mu\)M respectively. This may be due to their variable effects on multiple proteins which are differentially expressed in sensitive and resistant cells (Figure 5).

Table 3 Binding Energies of Ligand Molecules (S3c, S5b and S6c) and Standard Drugs with Target Proteins

| S.No. | Protein Targets | Standard Drugs | Standard | S3c | S5b | S6c |
|-------|----------------|----------------|----------|-----|-----|-----|
|       |                |                | Binding Energies (Kcal/mol) |     |     |     |
| 1     | p\textsuperscript{110b}/PI3K | Wortmannin | –9.9 | –9.0 | –8.5 | –7.9 |
| 2     | EGFR | Cetuximab | | mab\textsuperscript{k} | –7.1 | –6.9 | –6.3 |
| 3     | VEGFR | Sunitinib/Sorafenib | | –9.3/-10.3 | –6.7 | –8.6 | –6.9 |
| 4     | PDGFR | Sunitinib/Sorafenib | | –5.5/-6.7 | –5.2 | –5.3 | –4.6 |
| 5     | BCR-ABL | Imatinib | | –9.3 | –5.3 | –5.6 | –5.8 |
| 6     | RET | Vandetanib | | –9.5 | –8.9 | –8.5 | –6.8 |
| 7     | c-KIT | Sorafenib | | –8.5 | –8.1 | –7.8 | –6.6 |
| 8     | c-Raf | Sorafenib | | –8.8 | –7.7 | –8.1 | –6.6 |
| 9     | ALK | Crizotinib | | –8.9 | –7.5 | –7 | –5.8 |
| 10    | B-Raf | Sorafenib | | –10.0 | –9 | –8.8 | –7.4 |
| 11    | CTLA-4 | Ipilimumab | | mab\textsuperscript{k} | –5.5 | –5.7 | –5.0 |

Note: *mab, Monoclonal antibody, structure not available.
Docking Evaluation

Synthesized compounds S3c, S5b, and S6c that exhibited significant in vitro anticancer activities were selected as ligands and docked against multiple protein targets such as EGFR, VEGFR, PDGFR, \( p^{110\alpha} \)/PI3K, RET, BCR-ABL, c-KIT, c-Raf, B-Raf, CTLA-4, and ALK. These targets were selected based upon their relative role in tumor development and are implicated in various cell signaling pathways. Further, the results of the docking study are summarized in Table 3. These results indicated that selected ligands demonstrated favorable interactions with multiple protein targets, which coincides with our experimental findings. Furthermore, compound S3c formed several hydrogen bonds with PDGFR, c-KIT, and ALK with the lowest binding energy values −5.2 Kcal/mol, −8.1 Kcal/mol, and −7.5 Kcal/mol respectively. Likely, compound S5b showed favorable docking against PDGFR, VEGFR, c-Raf, and CTLA-4 with binding energy values i.e −5.3 Kcal/mol, −8.6 Kcal/mol, −8.1 Kcal/mol, −5.7 Kcal/mol respectively that is comparable to standard inhibitors. It was analyzed that profound binding affinity was shown by compound S6c against BCR-Ab1 with the minimum free energy of binding −5.8 Kcal/mol. It was observed that these three derivatives possessed comparative binding affinity (possibly inhibitory) against EGFR and CTLA-4. As the \( p^{110\alpha} \) isoform of PI3K is mainly involved in the development of ovarian cancer, all three

Figure 6 Post docking analysis visualized by Discovery Studio Visualizer in both 2D and 3D poses in the protein structures of \( p^{110\alpha} \) isoform of PI3K. Interaction between S3c and \( p^{110\alpha} \) isoform of PI3K (A and B), S5b and \( p^{110\alpha} \) isoform of PI3K (C and D). 3D poses (A and C) and 2D (B and D).
ligands were found to be active against this target. Compounds S3c, S5b, and S6c exhibited marked inhibition against α isoform of PI3K with binding energy values of −9.0 Kcal/mol, −8.5 Kcal/mol, and −7.9 Kcal/mol that is comparable to the reference compound i.e. −9.9 Kcal/mol.

Binding mode and 2D interactions of compounds S3c & S5b with α isoform of PI3K, EGFR, VEGFR, and PDGFR are expressed in Figures 6–9 respectively, demonstrating that these derivatives can significantly inhibit multiple targets in cellular pathways.

Discussion
In this study, we demonstrated the synthesis of new 2-aminothiazole and 2-aminopyridine derivatives, which possess amino acid moieties to execute antioxidant and anticancer potential. Interest in the chemotherapeutic activity of thiazoles was potentiated by the discovery of natural antineoplastic agents such as tiazofurin, bleomycin, netropsin, and thiazole netropsin. Moreover, many clinically useful anticancer drugs possess thiazole and pyridine as active moieties including dactinomycin and Imatinib mesylate respectively.
The network-medicine approach implies a promising strategy by targeting several proteins in a network by rewiring network structures particularly proteins, as denatured or misfolded protein will induce vulnerability for chemoresistance and subsequent failure of cancer therapies.45 We demonstrated that our synthesized compounds can target multiple protein targets such as EGFR, VEGFR, PDGFR, \( p^{110a} \)/PI3K, RET, BCR-ABL, c-KIT, c-Raf, B-Raf, CTLA-4, and ALK and thereby validating the concept of network-based approach. Derivative S3c showed an equivalent capacity of inhibition against PDGFR, c-KIT, and ALK target with lowest binding energy values \(-5.2 \text{ Kcal/mol}, \ -8.1 \text{ Kcal/mol}, \ -7.5 \text{ Kcal/mol} \) respectively. Moreover, compound S5b exhibited strong bindings against cancer targets PDGFR, VEGFR, c-Raf, and CTLA-4 with energy values of \(-5.3 \) Kcal/mol, \(-8.6 \) Kcal/mol, \(-8.1 \) Kcal/mol, \(-5.7 \) Kcal/mol respectively. The \( p^{110a} \) isoform of PI3K is the main target involved in the development of ovarian cancer,8 and all three ligands (S3c, S5b, and S6c) displayed a good binding affinity with this target with binding energy values of \(-9.0 \) Kcal/mol, \(-8.5 \) Kcal/mol and \(-7.9 \) Kcal/mol respectively.

Redox imbalance and oxidative stress are hallmarks of cancers, so, antioxidants play a significant role in cancer treatment by ameliorating levels of free radicals and oxidative stress.37,38 Therefore, the antioxidant activity of synthesized compounds was performed to

---

**Figure 8** Post docking analysis visualized by Discovery Studio Visualizer in both 2D and 3D poses in the protein structures of VEGFR. Interaction between S3c and VEGFR (A and B), S5b and VEGFR (C and D). 3D poses (A and C) and 2D (B and D).
preliminary screen the free radical scavenging potential. Based on our results, five compounds S3b, S3c, S4c, S5b, and S6c with an EC$_{50}$ value of 16.25 μg/mL, 14.16 μg/mL, 17.03 μg/mL, 12.97 μg/mL, and 15.19 μg/mL respectively were selected for evaluation of the in vitro anticancer potential in comparison to ascorbic acid.

Cisplatin is clinically used in a wide spectrum of cancers, however, its therapeutic implications are limited by its toxicities, and tumor resistance. To overcome, we incorporated amino acids conjugation into thiazole and pyridine scaffold to minimize toxicities by enhancing selective cellular permeability of the heterocyclic scaffold. Cellular mechanisms responsible for cisplatin resistance are multifactorial that restrict their clinical use. Our results revealed that compounds S3c, S5b, and S6c were found to be more active in cisplatin-resistant cell lines than the parent cells by displaying less IC$_{50}$ values, 11.52 μM, 14.32 μM, and 15.41 μM respectively relative to the standard cisplatin which was 16.43 μM along with stable RF values of 0.74, 0.56, and 0.49 respectively. RF determines the ability of a compound to induce cell death in resistant cells and RF value less than 2 is an indication of significant activity of a compound against resistant cell lines. The RF for all the tested compounds S3b, S3c, S4c, S5b, and S6c were noteworthy ie 1.42, 0.74, 1.31, 0.56, and 0.49 respectively, while, for cisplatin is 26.93. This may be due to their variable effects on genes and proteins which are

Figure 9 Post docking analysis visualized by Discovery Studio Visualizer in both 2D and 3D styles with PDGFR. Interaction between S3c and PDGFR (A and B), S5b and PDGFR (C and D). 3D poses (A and C) and 2D (B and D).
differentially expressed in sensitive and resistant cells such as oncogenes (c-fos, c-myc, H-ras, c-jun, and c-abl), tumor suppressor genes (p53), transcription factors, and regulatory proteins involved in signal transduction pathways. Moreover, compound S3c demonstrated equal effectiveness in both parent and cisplatin-resistant ovarian cancer cells with an IC₅₀ value of 15.57 µM, 11.52 µM respectively.

Therefore, it can be inferred that compounds S3c, S5b, and S6c can be considered as potential leads or hits for the development of new anticancer agents for cisplatin-resistant ovarian cancer. More detailed studies are required to delineate the detailed underlying mechanism of these compounds in different cancer cell lines and targets.

Conclusion
In conclusion, our findings demonstrated that derivatives S3c, S5b and S6c were found to be more active in cisplatin-resistant ovarian cancer cell lines than cisplatin-sensitive cells. Therefore, these compounds may be used as potential anticancer lead candidates for further screening because they might reduce oxidative stress in cancerous cells and also possess multiple target inhibitory potential.

Author Contributions
All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published, and agree to accountable for all aspects of the work.

Funding
This work was supported by Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions No: 2019SHIBS0004, Shenzhen, 518055, China.

Disclosure
The authors report no conflicts of interest for this work.

References
1. Ghoneum A, Said N. PI3K/AKT-mTOR and NFkB pathways in ovarian cancer: implications for targeted therapeutics. Cancers. 2019;11: 949. doi:10.3390/cancers11070949
2. Wu YH, Huang YF, Chen CC, Huang CY, Chou CY. Comparing PI3K/Akt inhibitors used in ovarian cancer treatment. Front Pharmacol. 2020;11:206. doi:10.3389/fphar.2020.00206
3. Lee MJ, Ye AS, Gardino AK, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 2012;149(4):780–794. doi:10.1016/j.cell.2012.03.031
4. Zhang F, Ren C, Lau KT. A network medicine approach to build a comprehensive atlas for the prognosis of human cancer. Brief Bioinform. 2016;17(6):1044–1059. doi:10.1093/bib/bbw076
5. Liu X, Wu J, Zhang D, et al. Network pharmacology-based approach to investigate the mechanisms of Heliotropia diffusa willd. in the treatment of gastric cancer: Evid Based Complement Alternat Med. 2018; doi:10.1155/2018/7802639
6. Nasser AA, Eissa IH, Oun MR. Discovery of new pyrimidine-5-carboxitile derivatives as anticancer agents targeting EGFRWT and EGFRccrim. Org Biomol Chem. 2020;18 (38):7608–7634. doi:10.1039/D0OB01557A
7. Pashon T, Linding R. Network medicine. FEBS Lett. 2008;58 2:1266–1270. doi:10.1016/j.ferb.2008.02.011
8. Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797. doi:10.1038/s41419-020-02998-6
9. Amable L. Cisplatin resistance and opportunities for precision cancer. Pharmacol Res. 2016;106:27–36. doi:10.1016/j.phrs.2016.01.001
10. Navaya PN, Kapthe A, Daima HK. Nanomedicine in sensing, delivery, imaging and tissue engineering: advances, opportunities and challenges. Nanoscience. 2019;5:30–56.
11. Navaya PN, Kapthe A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converge. 2019;6:23.
12. Chen S, Chang J. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int J Mol Sci. 2019;20 (17):4136. doi:10.3390/ijms20174136
13. Ferreira JA, Peixoto A, Neves M, et al. Mechanisms of cisplatin resistance and targeting of cancer stem cells: adding glycosylation to the equation. Drug Resist. 2016;24:34–54.
14. Zhou J, Kang Y, Chen L, et al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol. 2020;11:343.
15. Vitaku E, Smith DT, Njardarson JT. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J Med Chem. 2014;57:10257–10274. doi:10.1021/jm501010b
16. Bosenbecker J, Bareno VDO, Difibato R, et al. Synthesis and antioxidant activity of 3-(pyridin-2-yl ethyl)-1,3-thiazolin(thiazolidin)-4-ones. J Biochem Mol Toxic. 2014;28:425–432. doi:10.1002/jbt.21581
17. Sra AM, Mastoura ME, Heba AH, et al. Synthesis and biological evaluation of some novel thiazole-based heterocycles as potential anticancer and antimicrobial agents. Molecules. 2019;24:539. doi:10.3390/molecules24050539
18. Hussein AM, Khames AA, El-Adasy AA, et al. Design, synthesis and biological evaluation of new 2-aminothiazole scaffolds as phosphodiesterase type 5 regulators and COX-1/COX-2 inhibitors. RSC Adv. 2020;10(50):29723–29736. doi:10.1039/D0RA05561A
19. Rodriguez-Rangel S, Bravin AD, Ramos-Torres KM, Brugarolas P, Sánchez-Rodríguez JE. Structure-activity relationship studies of four novel 4-aminothiazide K⁺ channel blockers. Sci Rep. 2020;10(1):52. doi:10.1038/s41598-019-56245-w
20. Hersi F, Omar HA, Al-Qawasmeh RA, et al. Design and synthesis of new energy restriction mimetic agents: potent anti-tumor activities of hybrid motifs of aminothiazoles and coumarins. Sci Rep. 2020;10 (1):2893. doi:10.1038/s41598-020-59685-x
21. El-Naggar AM, Eissa IH, Belal A, El-Sayed AA. Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5(4H)-ones as potential tubulin polymerization inhibitors targeting the colchicine binding site. RSC Adv. 2020;10 (5):2791–2811. doi:10.1039/C9RA0094F
Alizadeh SR, Hashemi SM. Development and therapeutic potential of 2-aminothiazole derivatives in anticancer drug discovery. Med Chem Res. 2021;1–36. doi:10.1007/s00444-020-02686-2

Gomha SM, Muhammad ZA, Abdel-aziz MR, Abdel-aziz HM, Gaber HM, Elaassere MM. One-pot synthesis of new thiazoloyl-pyridines as anticancer and antioxidant agents. J Heterocycl Chem. 2018;55(2):530–536. doi:10.1002/jhet.3088

Arun R, Ashok KCK. Synthesis, hydrolysis and pharmacodynamics profiles of novel prodrugs of mefenamic acid. Int J Carr Pharm Res. 2009;1:47–55.

Prakash KC, Raghavendra GM, Harisha R, et al. Design, synthesis and antimicrobial screening of amino acids conjugated 2-amino-4-arylthiazole derivatives. Int J Pharm Pharm Sci. 2011;3:120–125.

Locatelli M, Gindro R, Travaglia F, et al. Study of DPPH-scavenging activity: development of a free software for the correct interpretation of data. Food Chem. 2009;114:889–897. doi:10.1016/j.foodchem.2008.10.035

Ali-Saad SM, Hassan MF, Sherif AF. Synthesis and biological evaluation of some 2,4,5-trisubstituted thiazole derivatives as potential antimicrobial and anticancer agents. Arch Pharm Chem Life Sci. 2008;341:424–434. doi:10.1002/ardp.200800026

Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56–68. doi:10.1038/nrg2918

Laila A, Philip B, Charles C, et al. Synergy from combinations of (benzimidazole) monochloroaluminum(II) chloride with capsaicin, quercetin, curcumin and esplatin in human ovarian cancer cell lines. Anticancer Res. 2014;34:5453–5464.

Muthu G, Nuanjaen M, Darpan K. Facile synthesis and characterization of 2-aminothiazole-4-carboxy hydrazide. Int J Adv Pharm Res. 2011;2:27–29.

Hassan M, Farzana S, Uzma Y, et al. Preparation of optically active amino acid derivatives of some methylated 5-amino azaheterocycles. Turk J Chem. 2000;24:165–175.

Cyril O, Didier ML, Johan W, et al. Synthesis and anticorvulsant activity of N,N’-phthaloyl derivatives of central nervous system inhibitory amino acids. Arch Pharm Pharm Chem Med. 2001;334:323–331. doi:10.1002/1521-4184(200110)334:10<323::DOI:10.1002/jemer.2010.05.053

Abbas I, Gomha S, Elaassser M, Bauomi S. Synthesis and biological evaluation of new pyridines containing imidazole moiety as antimicrobial and anticancer agents. Turk J Chem. 2015;39(2):334–346. doi:10.3906/kim-1410-25

Gomha SM, Muhammad ZA, Abdel-aziz HM, Matar IK, El-Sayed AA. Green synthesis, molecular docking and anticancer activity of novel 1,4-dihydropyridine-3,5-Dicarbohydrazones under grind-stone chemistry. Green Chem Lett Rev. 2020;13(1):6–17. doi:10.1080/17518253.2019.1710268

Gomha SM, Abdelrazek FM, Abdelrahman AH, Metz P. Synthesis of some new pyridine-based heterocyclic compounds with anticipated antitumor activity. J Heterocycl Chem. 2018;55(7):1729–1737. doi:10.1002/jhet.3210

El-Naggar M, Almahl H, Ibrahim HS, Eldehna WM, Abdel-Aziz HA. Pyridine-ureas as potential anticancer agents: synthesis and in vitro biological evaluation. Molecules. 2018;23(6):1459. doi:10.3390/molecules23061459

Klaunig JE. Oxidative stress and cancer. Curr Pharm Des. 2018;24(40):4771–4778. doi:10.2174/13816122016890021512712

Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38(2):167–197.

Kruk J, Aboul-Enein HY. Reactive oxygen and nitrogen species in carcinogenesis: implications of oxidative stress on the progression and development of several cancer types. Mini Rev Med Chem. 2017;17(11):904–919. doi:10.2174/1389557517666170228115324
